EZZ Life Science Holdings Ltd (ASX: EZZ) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
EZZ Life Science Holdings Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$132.47 million
P/E Ratio
24.98
Dividend Yield
0.62%
Shares Outstanding
44.42 million
Earnings per share
0.081
Dividend per share
0.03
Year To Date Return
357.69%
Earnings Yield
4.00%
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
EZZ Life Science Holdings Ltd (ASX: EZZ)
Latest News
Healthcare Shares
Up 630% this year AND profitable! This small ASX healthcare share is glowing
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 05 Nov 2024 | $0.0200 | 100.00% | Final | 09 Dec 2024 |
| 16 May 2024 | $0.0150 | 100.00% | Interim | 17 Jun 2024 |
| 30 Oct 2023 | $0.0100 | 100.00% | Final | 08 Dec 2023 |
| 22 May 2023 | $0.0098 | 100.00% | Interim | 23 Jun 2023 |
| 03 Nov 2022 | $0.0045 | 100.00% | Final | 16 Dec 2022 |
| 09 Nov 2021 | $0.0045 | 100.00% | Final | 16 Dec 2021 |
EZZ ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About EZZ Life Science Holdings Ltd
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity,human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
EZZ Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Nov 2024 | $2.87 | $0.00 | 0.00% | 97,108 | $2.84 | $2.97 | $2.78 |
| 19 Nov 2024 | $2.88 | $0.06 | 2.13% | 36,867 | $2.82 | $2.90 | $2.82 |
| 18 Nov 2024 | $2.82 | $-0.13 | -4.41% | 104,647 | $2.90 | $2.95 | $2.78 |
| 15 Nov 2024 | $2.95 | $-0.01 | -0.34% | 30,558 | $2.91 | $2.99 | $2.88 |
| 14 Nov 2024 | $2.96 | $-0.04 | -1.33% | 20,541 | $3.00 | $3.06 | $2.87 |
| 13 Nov 2024 | $3.00 | $-0.05 | -1.64% | 98,136 | $3.10 | $3.10 | $2.86 |
| 12 Nov 2024 | $3.05 | $0.11 | 3.74% | 192,352 | $2.96 | $3.06 | $2.81 |
| 11 Nov 2024 | $2.94 | $0.08 | 2.80% | 122,176 | $2.76 | $2.99 | $2.72 |
| 08 Nov 2024 | $2.86 | $-0.05 | -1.72% | 126,117 | $2.83 | $3.07 | $2.83 |
| 07 Nov 2024 | $2.91 | $-0.12 | -3.96% | 331,282 | $2.97 | $3.05 | $2.82 |
| 06 Nov 2024 | $3.03 | $-0.16 | -5.02% | 79,977 | $3.20 | $3.30 | $3.01 |
| 05 Nov 2024 | $3.19 | $0.01 | 0.31% | 86,534 | $3.21 | $3.30 | $3.11 |
| 04 Nov 2024 | $3.18 | $-0.52 | -14.05% | 259,365 | $3.70 | $3.70 | $3.14 |
| 01 Nov 2024 | $3.70 | $0.20 | 5.71% | 180,392 | $3.45 | $3.72 | $3.43 |
| 31 Oct 2024 | $3.50 | $0.00 | 0.00% | 186,004 | $3.48 | $3.53 | $3.32 |
| 30 Oct 2024 | $3.50 | $0.10 | 2.94% | 161,944 | $3.40 | $3.51 | $3.35 |
| 29 Oct 2024 | $3.40 | $-0.04 | -1.16% | 176,563 | $3.42 | $3.57 | $3.40 |
| 28 Oct 2024 | $3.44 | $0.04 | 1.18% | 114,600 | $3.35 | $3.63 | $3.33 |
| 25 Oct 2024 | $3.40 | $-0.17 | -4.76% | 110,879 | $3.58 | $3.71 | $3.40 |
| 24 Oct 2024 | $3.57 | $0.02 | 0.56% | 125,309 | $3.62 | $3.87 | $3.55 |
| 23 Oct 2024 | $3.55 | $0.14 | 4.11% | 163,904 | $3.46 | $3.65 | $3.46 |
| 22 Oct 2024 | $3.41 | $-0.53 | -13.45% | 427,530 | $3.82 | $3.82 | $3.40 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 21 Aug 2024 | Ivan Oshry | Issued | 15,000 | $1,200 |
Issued under employee share plan.
|
| 21 Aug 2024 | Lily (Hao) Huang | Issued | 15,000 | $1,200 |
Issued under employee share plan.
|
| 21 Aug 2024 | Glenn Cross | Issued | 15,000 | $1,200 |
Issued under employee share plan.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Ivan Oshry | Non-Executive Director | Oct 2020 |
Mr. Oshry has more than 30 years of experience of legal practice in Australia and internationally, specializing in commercial and corporate law. Mr. Oshry was formerly a senior partner at Fluxmans Attorneys in Johannesburg and headed up the corporate department at Kemp Strang (which merged with Thomson Geer) in Sydney. He is Chair of the Risk Committee and a Member of the Human Resource Committee.
|
| Ms Lily (Hao) Huang | Non-Executive Director | Oct 2020 |
Ms. Huang has over 20 years of experience in the wealth management and banking industry. She has been working with Citi Group Australia since 2017 as Vice President of the APAC Desk of the Investment Partnerships Division. He is Member of the Risk Committee and Chair of the Human Resource Committee.
|
| Mr Mark (Qizhou) Qin | Chief Operating OfficerExecutive DirectorInterim Chief Executive Officer | Sep 2018 |
Mr. Qin is a co-founder of the Company with a track record of success in the skin care and health supplements industries. He has a background in management consulting and experience in sales and marketing. Mr. Qin also authored five books in sales and marketing for the consumer health industry between 2003 and 2008.
|
| Mr Glenn Walter Cross | Non-Executive ChairmanNon-Executive Director | Dec 2021 |
Mr. Cross has 40 years of experience in life science sector domestically and internationally, including over 20 years in senior executive capacity. He was formerly CEO and COO of AusBiotech over 13 years. He is a Member of the Risk Committee and a Member of the Human Resource Committee.
|
| Ms Natalie Sylvia Climo | Company Secretary |
-
|
|
| Anthony Guarna | Chief Financial Officer |
-
|
|
| Natalie Sylvia Climo | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Macquarie Holdings Pty Ltd | 17,016,000 | 38.31% |
| Jnj Mok Pty Ltd | 11,344,000 | 25.54% |
| Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 2,124,363 | 4.78% |
| Yong Cao | 1,760,000 | 3.96% |
| New Continent Australia Pty Ltd | 854,100 | 1.09% |
| Zhaoying Wang | 486,000 | 1.09% |
| Haitao Zheng | 470,000 | 1.06% |
| Mars Family Investment Pty Ltd Mars Family A/C) | 405,000 | 0.91% |
| Citicorp Nominees Pty Ltd | 400,614 | 0.90% |
| Jing Chen | 331,980 | 0.75% |
| Oren Danziger | 256,606 | 0.58% |
| Finclear Services Pty Ltd Superhero Securities A/C) | 156,009 | 0.35% |
| Warbont Nominees Pty Ltd Unpaid Entrepot A/C) | 152,850 | 0.34% |
| Xiaojing Wang | 150,000 | 0.34% |
| George Khouri | 130,000 | 0.29% |
| J P Morgan Nominees Australia Pty Ltd | 128,286 | 0.29% |
| BNP Paribas Noms Pty Ltd | 120,000 | 0.27% |
| Comsec Nominees Pty Ltd | 117,797 | 0.27% |
| Emma Michelle Sievwright | 115,688 | 0.26% |
| Stephen Anthony Mander | 113,040 | 0.26% |
